頁籤選單縮合
題 名 | 認識過動症ADHD用藥=Treatment of Attention Deficit Hyperactivity Disorder |
---|---|
作 者 | 林怡芬; 陳家豪; 陳麗芳; | 書刊名 | 藥學雜誌 |
卷 期 | 26:1=102 2010.03[民99.03] |
頁 次 | 頁14-19 |
分類號 | 418.21 |
關鍵詞 | 注意力不足過動症; 過動症用藥; 何謂過動症; Attention deficit hyperactivity disorder; Atomoxetine; |
語 文 | 中文(Chinese) |
中文摘要 | 注意力不足過動症 (簡稱 ADHD)是一種遺傳性的神經生理的疾病,主要特徵表現包括過動、衝動與注意力難集中。全世界約有 4% ~ 8%的孩童受到影響,其致病因素包含多巴胺神經系統與正腎上腺素神經系統的迴路異常有關。其治療方式包含藥物與非藥物療法。目前,腦部的興奮劑最常被建議用來當作第一線藥物治療。雖然 atomoxeine是治療 ADHD的另一選擇,其為選擇性抑制正腎上腺素再回收的藥物且是唯一能有效治療 ADHD之非興奮劑。然而 atomoxeine僅為 ADHD二線治療選擇。其他用來治療 ADHD的藥物包括 clonidine, guanfacine, venafaxine, SSRI's, TCA及bupropion。此外,藥物合併心理治療、介入行為治療也可降低 ADHD負面的徵狀,包括品性疾患或是反社會人格疾患的比例。 |
英文摘要 | Attention deficit hyperactivity disorder (ADHD) is a genetically based neurobiologcal disorder characterized by hyperactivity, impulsivity and difficulties in sustaining attention. That was influenced approximately 4% ~ 8% children worldwidely and the pathophysiology was thought to involve alteration in dopaminergic and noradrenergic pathways. Pharmacological and non-pharmacological interventions were the way for ADHD treatment. Nowadays, cerebral stimulants are the most commonly suggested as first-line therapy for ADHD. Although the atomoxetine, the newest treatment option for ADHD, was a selective norepinephrine reuptake inhibitor and the only effective non-stimulant treatment for ADHD, it was merely suggested as second-line therapy. The others, including clonidine, guanfacine, venafaxine, SSRI's, TCA and Bupropion, used in the treatment of ADHD had been reported. Additionally, drug therapy with psychoeducation and behavioral intervention may decrease negative outcome of ADHD, including the rate of conduct disorder and adult antisocial personality disorder. |
本系統中英文摘要資訊取自各篇刊載內容。